Neurocrine's Elagolix Misses Main Study Goal

Updated from 1:21 a.m. EDT

Neurocrine Biosciences(NBIX Quote) designed the latest phase II study of its endometriosis drug elagolix with so many endpoints that it shouldn't be surprising to discover that some of the efficacy measures succeeded while others failed.

A potential problem for Neurocrine, however, is that one of the endpoints that came up short was the primary, or main goal, of the study, while another was an endpoint suggested by the U.S. Food and Drug Administration.

Elagolix is the lead drug in Neurocrine's research pipeline and the asset that investors hope erases the stigma attached to the company stemming from the disastrous FDA rejection of its sleeping pill indiplon three years ago. ...